Home > Publications database > Presence of tumor DNA in aqueous humor is correlated with high risk uveal melanoma. > print

001     301761
005     20250605113454.0
024 7 _ |a 10.1038/s41598-025-03915-7
|2 doi
024 7 _ |a pmid:40461505
|2 pmid
037 _ _ |a DKFZ-2025-01141
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Barwinski, Nicole
|0 P:(DE-He78)a5ad9eedfd2684dd5c4137ec293529e7
|b 0
|u dkfz
245 _ _ |a Presence of tumor DNA in aqueous humor is correlated with high risk uveal melanoma.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1749042733_17381
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Metastatic risk stratification is critical for uveal melanoma (UM) management, as approximately up to half of patients develop metastatic disease. Current prognostication for patients undergoing eye-preserving therapies relies on tumor staging and molecular analysis of tumor tissue obtained through potentially invasive biopsy, which can be challenging. While liquid biopsy using cell-free DNA (cfDNA) has emerged as a less invasive alternative for other cancers, studies have shown limited utility of blood-derived cfDNA in UM due to low tumor DNA fractions. This study investigates the potential of aqueous humor (AH) and vitreous body (VB) aspirates as alternative sources of tumor DNA for molecular prognostication in UM patients at the time of diagnosis. In this prospective study, AH and/or VB samples were collected from 96 consecutive UM patients undergoing enucleation, transretinal endoresection or transretinal biopsy. DNA was extracted from the ocular fluids and analyzed for the presence of tumor-derived DNA using deep amplicon sequencing targeting mutations in GNAQ and GNA11. This approach achieved an average read depth of 120,000, enabling highly sensitive detection of tumor-specific variants. Tumor DNA was detected in at least one ocular fluid (AH or VB) in 43 of 88 evaluable patients (49%), with variant allele fractions (VAFs) ranging from 0.3 to 50%. Of these positive cases, tumor DNA was identified in VB only in 22 patients, AH only in 5 patients, and both fluids in 16 patients. Importantly, tumor DNA in AH was almost exclusively observed in patients with monosomy 3 UM. No significant correlation was found between the presence of tumor DNA in either ocular fluid and primary tumor size or location. Liquid biopsy of AH and VB offers a promising, minimally invasive strategy for obtaining tumor DNA in nearly half of UM patients at diagnosis. The strong association between detectable tumor DNA in AH and monosomy 3 status warrants further investigation and may offer valuable insights into UM biology and dissemination mechanisms. This approach may improve risk stratification and inform personalized treatment strategies for patients with UM.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Uveal melanoma
|2 Other
650 _ 7 |a Aqueous humor
|2 Other
650 _ 7 |a Biomarkers
|2 Other
650 _ 7 |a CfDNA
|2 Other
650 _ 7 |a Liquid biopsy
|2 Other
650 _ 7 |a Ocular liquids
|2 Other
650 _ 7 |a Prognostic testing
|2 Other
650 _ 7 |a Vitreous body
|2 Other
650 _ 7 |a DNA, Neoplasm
|2 NLM Chemicals
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a GNA11 protein, human
|2 NLM Chemicals
650 _ 7 |a GNAQ protein, human
|2 NLM Chemicals
650 _ 7 |a GTP-Binding Protein alpha Subunits, Gq-G11
|0 EC 3.6.5.1
|2 NLM Chemicals
650 _ 7 |a GTP-Binding Protein alpha Subunits
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Uveal Neoplasms: genetics
|2 MeSH
650 _ 2 |a Uveal Neoplasms: pathology
|2 MeSH
650 _ 2 |a Uveal Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Aqueous Humor: metabolism
|2 MeSH
650 _ 2 |a Melanoma: genetics
|2 MeSH
650 _ 2 |a Melanoma: pathology
|2 MeSH
650 _ 2 |a Melanoma: diagnosis
|2 MeSH
650 _ 2 |a Uveal Melanoma
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a DNA, Neoplasm: genetics
|2 MeSH
650 _ 2 |a DNA, Neoplasm: analysis
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Biomarkers, Tumor: genetics
|2 MeSH
650 _ 2 |a Vitreous Body: metabolism
|2 MeSH
650 _ 2 |a Mutation
|2 MeSH
650 _ 2 |a GTP-Binding Protein alpha Subunits, Gq-G11: genetics
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a GTP-Binding Protein alpha Subunits
|2 MeSH
700 1 _ |a Lever, Mael
|b 1
700 1 _ |a Rating, Philipp
|b 2
700 1 _ |a Jabbarli, Leyla
|b 3
700 1 _ |a Fiorentzis, Miltiadis
|b 4
700 1 _ |a Bechrakis, Nikolaos E
|b 5
700 1 _ |a Lohmann, Dietmar R
|b 6
700 1 _ |a Zeschnigk, Michael
|b 7
700 1 _ |a Le Guin, Claudia H D
|b 8
773 _ _ |a 10.1038/s41598-025-03915-7
|g Vol. 15, no. 1, p. 19406
|0 PERI:(DE-600)2615211-3
|n 1
|p 19406
|t Scientific reports
|v 15
|y 2025
|x 2045-2322
909 C O |o oai:inrepo02.dkfz.de:301761
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)a5ad9eedfd2684dd5c4137ec293529e7
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-07-29T15:28:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-07-29T15:28:26Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-07-29T15:28:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21